Please login to the form below

Not currently logged in
Email:
Password:

Enterprise Therapeutics appoints CEO

Dr John Ford will lead the UK drug discovery company

Enterprise Therapeutics Dr John FordBrighton, UK-based respiratory diseases specialist Enterprise Therapeutics has appointed Dr John Ford as chief executive officer, with immediate effect.

In his new role, Dr Ford will oversee the development of the company's novel muco-regulatory therapies for patients suffering with chronic obstructive pulmonary disease, cystic fibrosis and severe asthma.

He joins the drug discovery firm from Xention Discovery, where he had served as chief scientific officer since co-founding the company in 2002.

Dr Ford also brings experience from Ario Pharma, where he is currently chief executive officer and co-founder, and Metrion Biosciences, where he serves as co-owner and investor director.

Previously, Dr Ford has worked as general manager of Akarna Therapeutics' UK operations, chief operating officer of Dezima Pharma and a team leader for cell-based drug discovery campaigns at BioFocus Discovery.

Dr Peter Finan, chairman of Enterprise Therapeutics, said: “John's experience in ion channels, drug development, and biotech fundraising position him uniquely to lead Enterprise Therapeutics moving forward.

“His expertise will complement the existing team and we are thrilled to have him on board.”

3rd November 2016

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics